Adaptive Biotechnologies: MRD Momentum, a Plan to Split, and the Q2 2026 Ledger

Ticker: ADPT • EPS (not reported in the release) • earnings surprise implications • EPS consensus considerations • revenue forecast updated

Snapshot: the numbers you actually care about in Q2 2026

Adaptive Biotechnologies Corporation reported second-quarter 2026 revenue of $71.6 million, with the MRD business contributing $66.2 million, up 33% from the second quarter of 2025. The Immune Medicine segment posted $5.4 million in revenue, which was down 40% year over year. Genentech-related revenue was zero for the quarter, and excluding the Genentech contribution, Immune Medicine revenue rose 8% versus the prior year.

The company also highlighted a volant increase in clonoSEQ test volume, delivering 36,111 tests in Q2 2026, a 43% uptick from the prior-year period.

Strategic stance: “two businesses, one plan” and the capital shuffle

Management framed the results within a broader plan to separate the MRD and Immune Medicine businesses, a step they described as a pathway to unlocking longer-term value. CEO Chad Robins praised the quarter as “exceptional,” noting the combination of operating performance and a fortified balance sheet while signaling the structural move to separate the two lines.

On the balance sheet and capital structure front, Adaptive completed a $345 million zero-coupon convertible senior notes offering and repaid the OrbiMed Purchase Agreement, aiming to bolster financial flexibility to support strategic priorities. The balance sheet improvement dovetails with the company’s longer-term vision to reallocate resources as MRD growth continues to outpace other segments.

The MRD story is the core of the quarter

The MRD segment’s performance stood out: $66.2 million in quarterly revenue and a 33% year-over-year growth rate. This was underscored by MRD-related commentary in the press release and the accompanying management narrative, which emphasized the clinical and biopharma footprint of MRD as a durable growth pillar.

The Immune Medicine line, while smaller in the quarterly mix, illustrated the volatility inherent in a diversified biotech portfolio: a 40% YoY decline in revenue, offset by the note that excluding Genentech revenue, Immune Medicine still rose 8% YoY. The Genentech agreement is the variable here; with zero revenue in the quarter, investors will be watching how this relationship evolves and whether the segment can regain momentum.

Guidance and near-term outlook

Adaptive raised its full-year 2026 MRD revenue guidance to a range of $268 million to $278 million, implying annual MRD growth of about 26% to 31%. That’s the big number to anchor expectations for the rest of the year and a focal point for the company’s earnings narrative.

The overall revenue cadence remains anchored by MRD, with Immune Medicine acting as a potential upside or risk depending on Genentech-related revenue arrangements. As with many biotech disclosures, the absence or presence of collaboration revenue can swing the reported numbers meaningfully on a quarterly basis.

What this means for the sector and peers

The press release reinforces a familiar theme in biotechs: a high-growth, mission-critical primary business (MRD) backed by a smaller, more uncertain ancillary line (Immune Medicine). The plan to separate MRD from Immune Medicine could unlock value by giving each business its own capitalization path, risk profile, and potential suitors or strategic partners. For sector peers, the story underscores a pattern where investor focus shifts to scalable core franchises and structural moves—such as spin-offs or separations—that aim to crystallize value beyond one-off quarterly receipts.

The convertible notes issuance, coupled with a strategic likelihood of separation, also signals a preference for balance-sheet flexibility over near-term leverage for non-operational aims. For investors tracking EPS and earnings surprises, the immediate implication is clear: this release foregrounds revenue growth and strategic repositioning rather than a near-term EPS beat. Analysts may look to the EPS consensus trajectory in subsequent quarters as the MRD engine’s expansion stabilizes and the Immune Medicine story firms up.

Close with a practical reading

Adaptive’s Q2 2026 results tilt toward MRD-led growth with a deliberate corporate reshaping on the horizon. The revenue forecast for MRD remains the backbone, and the company’s ability to translate that growth into shareholder value will hinge on how cleanly it can separate MRD from Immune Medicine and how effectively it manages Genentech interactions going forward.

In the near term, expect attention on the trajectory of the MRD revenue line, the pace of the planned separation, and how the balance sheet flexes as the company navigates additional capital initiatives. If the MRD growth trajectory continues and the split unlocks value, the stock story could shift from “how much can MRD grow this quarter?” to “how will the separated entities deploy capital and attract strategic backing?”